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Keeping in mind the caveats associated with cross trial comparisons, the analysis
suggested increased effectiveness of LEN over BORT in MM patients with refracto-
ry/relapsed disease. These findings, along with its oral route of administration and
established safety profile suggest that LEN should be the preferred agent for refrac-
tory/relapsed MM.
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COMPARING BRENTUXIMAB VEDOTIN OVERALL SURVIVAL DATA TO
STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA (HL) POST-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
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OBJECTIVES: Health care decision makers require estimates of the incremental
health benefit of any new technology relative to existing treatments. For treat-
ments targeting small patient subgroups, randomised controlled trial (RCT) data is
often unavailable requiring alternative methods to estimate comparative efficacy.
We illustrate two approaches, using the example of brentuximab vedotin.
METHODS: Brentuximab vedotin has been studied in HL patients relapsed follow-
ing ASCT (SG035-0003; Younes et al, JCO 2012). We compare 2-year survival data
from the 0003 study to: (1) A systematic review in ASCT failures – carried out
according to standard methods; no restrictions on study design/treatment. Per-
centages of patients alive at six-monthly intervals for up to five years were ex-
tracted. Comparative graphs were produced, with proportions of patients alive in
each study versus time; each point sized to reflect number of patients/study (2) A
large observational study, adjusted to reflect prognosis in 0003 – Martinez 2010,
reported OS according to whether patients had 0, 1 or 2 risk factors. Results were
reported for chemotherapy/radiotherapy and allogeneic SCT. Survival curves
for these comparators were re-weighted to reflect the proportion of patients with 0,
1 or 2 risk factors in the 0003 trial. RESULTS: Thirty-one studies reported retriev-
able OS for radiotherapy, chemotherapy, palliative care, or allogeneic SCT or ASCT.
OS for brentuximab vedotin was higher than or very similar to all but five small
(n13–38) studies. The adjusted Martinez 2010 comparison estimated 2 year OS of
48% and 65% for chemotherapy/radiotherapy and ASCT. OS for brentuximab
vedotin at 2 years is 65% comparing favourably to Martinez 2010. CONCLUSIONS:
Both methods suggested a favourable OS profile for brentuximab vedotin when
compared to other reported data sets. If available, access to individual patient data
from the Martinez 2010 study would allow use of more advanced methods to adjust
for potential confounders.
SYSTEMIC DISORDERS/CONDITIONS - Cost Studies
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ECONOMIC EFFICIENCY OF FERRIC CARBOXYMALTOSE TO TREAT OR PREVENT
IRON DEFICIENCY ANEMIA: VALUE TO THE PORTUGUESE HOSPITALS
Ferreira D, Silva M, Vandewalle B, Félix J
Exigo Consultores, Alhos Vedros, Portugal
OBJECTIVES: Among the approved intravenous iron formulations, ferric carboxy-
maltose (Ferinject®) is the most efficacious in the treatment or prevention of iron
deficiency anemia, it’s less burdensome to administer (easier and shorter time
administration) and it reduces the need for expensive resource utilization like
erythropoietin and blood transfusions. The objective was to develop a tool to assess
the relative cost-efficiency of different intravenous iron formulations in the per-
spective of the Portuguese hospitals. METHODS: A fully parameterizable Mi-
crosoft® Excel based tool was developed to compare the economic efficiency of
intravenous iron formulations available to the Portuguese hospitals: ferric car-
boxymaltose (Ferinject®); ferric hydroxide saccharose (generic and Venofer®); fer-
ric hydroxide dextran (Cosmofer®). Economic efficiency was calculate as the bal-
ance between hospitals incurred costs relative to the number of patients to be
treated, the dose and number of administrations of intravenous iron, and the need
for erythropoietin and blood transfusions. The tool default values are from a liter-
ature review used to populate the model. The tool allows studying the cost and
benefits of treating/preventing chronic kidney disease, inflammatory bowel dis-
ease, chemotherapy, and orthopedic surgery related anemia. RESULTS: Ferric hy-
droxide saccharose (generic) is to the most used and lower price intravenous iron in
Portugal. Relative to generic ferric hydroxide saccharose (FHS), ferric carboxymalt-
ose (FC) is estimated to lower mean per patient annual costs in all four anemic
conditions in major hospitals: 3,087.60€ (FC) vs. 3,482.20€ (FHS) for chronic kidney
disease; 2,195.75€ (FC) vs. 2,427.4€ (FHS) for inflammatory bowel disease; 3,626.17€
(FC) vs. 3,793.13€ (FHS) for chemotherapy; and 3,485.74€ (FC) vs. 3,849.47€ (FHS) for
orthopedic surgery. These results were consistent irrespective of the type of
hospital. CONCLUSIONS: This is a valuable tool to inform hospital decison makers
about the economic value of ferric carboxymaltose as compared to other intrave-
nous iron formulations.
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SOCIETAL BURDEN ASSOCIATED WITH NEUROPATHIC PAIN IN EUROPE
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OBJECTIVES: Neuropathic Pain (NeP) is a common disorder that can be chronic,
severe and disabling, While the burden regarding quality of life and health care
costs is understood, societal costs are less researched. This analysis addresses the
implications in terms of work productivity loss and caregiver needs. METHODS:
Data were drawn from the 2012 Adelphi NeP Disease Specific Programme, a, cross-
sectional survey of 121 primary care physicians and 292 specialists and their pa-
tients run in five European countries (France, Germany, Italy, Spain and the UK).
Physicians provided data relating to diagnosis, treatment patterns and caregiver
requirements, patients were invited to fill a self-completion questionnaire includ-
ing the Work Productivity and Activity Impairment (WPAI) questionnaire.
RESULTS:A total of 3956 patients were included, of whom 2639 were of working age
and 1341 in either full or part time employment. 23% of those employed were
currently on sick leave, with mean duration of absence being 10 weeks. A total of
751 patients completed the WPAI; of whom 30% reported that NeP had stopped
them from working (limited periods or permanently). These patients reported ab-
senteeism from work 23% of the time. Whilst at work, on a scale of 0 (no effect) to
10 (complete prevention from work) patients reported a mean score of 4.4, implying
significantly reduced on-the-job effectiveness. Regarding regular daily activities
(housework, shopping etc.) on a similar scale from 0 to 10 patients again reported a
value of 4.4; 19% of patients had a caregiver responsible for their daily activities.
The most common caregiver was partner/spouse (66%) while only 15% received
care from a professional caregiver. The mean amount of care provided was 27
hours per week across Europe, ranging from 10 hours (France) to 48 hours (Italy).
CONCLUSIONS: This abstract implies evidence suggesting a major societal burden
within humanistic and economic societal burden associated with NeP in Europe.
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NUMBER NEEDED TO TREAT (NNT) AND COST ESTIMATION TO ACHIEVE A
MAJOR MOLECULAR RESPONSE (MMR) IN NEWLY DIAGNOSED CHRONIC
MYELOID LEUKEMIA PATIENTS IN GREECE
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OBJECTIVES: NNT can be a useful approach to compare treatments in the absence
of direct comparative clinical trials. Imatinib, nilotinib and dasatinib are approved
as first-line treatments for patients newly diagnosed with Philadelphia chromo-
some positive chronic myeloid leukemia in the chronic phase (CP-CML). The objec-
tive of this analysis is to compare these treatments with regards to: (1) the NNT to
achieve one MMR by 12 months (2) the cost of achieving one MMR and the annual
cost treatment including of adverse events (AEs) from the perspective of the Greek
National Health System (NHS). METHODS: MMR and AE rates were taken from the
CML-CP frontline trials –DASISION (dasatinib 100mg QD vs. imatinib 400mg QD)
and ENESTnd (nilotinib 300mg BID vs imatinib 400mg QD). The NNT was calculated
as the inverse of the MMR rate by 12 months (1/MMR). AE management costs were
estimated from patient records at Evangelismos Hospital and multiplied by the
incidence reported in the trials. RESULTS: The nilotinib NNT was 51% lower than
the imatinib NNT in ENESTnd (1.8 vs. 3.7) and the dasatinib NNT was 39% lower that
the imatinib NNT in DASISION (2.2 vs. 3.6). Annual cost of nilotinib including cost of
AEs is estimated at €34.349, dasatinib €35.504 and of imatinib €25.040. The cost of
achieving 1 MMR is €62.453 for nilotinib, €78.389 for dasatinib and €92.741 for ima-
tinib. Therefore, the cost of achieving 1 MMR with nilotinib is lower by 20,33% vs.
dasatinib and 33% vs. imatinib. CONCLUSIONS: The NNT findings and the differ-
ential cost of managing AEs in each treatment from this evaluation suggests that
nilotinib provides better clinical outcomes and would result in lower costs for
hematologic AE management from the perspective of the Greek NHS.
PSY9
REAL-LIFE COST-ANALYSES OF CHRONIC LOW-BACK PAIN PATIENTS WITH
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1University of Southern Denmark, Odense, Denmark, 2Pfizer Denmark, Ballerup, Denmark,
3Aarhus Rheumatologic Clinic, Aarhus, Denmark
OBJECTIVES:To evaluate the health care and productivity costs in chronic low back
pain (CLBP) patients with a probable neuropathic pain (NeP) component before and
after the initiation of pregabalin, gabapentin or a TCA (tricycle antidepressant).
METHODS: Patients with primary diagnosis of CLBP (ICD-10: M43, M45-48, M50-51,
M53-54) and at least two prescription claims for either pregabalin, gabapentin or a
TCA were identified using data from the National Patient Registry, the Medicinal
Registry, and other registries (2004-2010). Patients identified with generalized anx-
iety disorders or seizures were excluded. The index date was considered the first
prescription for pregabalin, gabapentin or a TCA. Descriptive assessments of
health care and productivity costs were conducted 12 months pre and 12 months
post the index date using the full dataset. To control for selection bias, a propensity
score matched cohort controlling for age, gender, socioeconomic status, education,
depression, and health care resource use was also conducted. Statistical tests per-
formed were Wilcoxon (0.05). RESULTS: A total of 6,028 of 7,282 CLBP patients
with NeP met the inclusion criteria (treatment courses included: 3,507 TCA; 2,735
gabapentin; 1,293 pregabalin). Twelve months health care costs increased signifi-
cantly in all 3 groups (€377 - €1,113) (P0.001). Matched sub-analyses covering 1,217
patients in each group showed similar significant health care cost increases; how-
ever, the pregabalin group was the only group to result in a significant reduction in
hospitalization costs (P0.03). Across all three groups number of job losses was
reduced, whereas long-term sickness increased; however, insignificantly so in the
pregabalin group. CONCLUSIONS: This study showed increasing healthc are costs
12 months after the initiation of NeP drug treatment in CBLP patients with NeP. In
matched analyses the increased health care costs in the pregabalin group were
partly offset by significant savings in hospitalization costs. Production lost in-
creased in all three groups; however, only significant in the TCA and gabapentin
groups.
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OBJECTIVES: Hereditary angioedema (HAE) is a rare and potentially life-threaten-
ing condition. The efficacy of acute HAE treatments has not been assessed in head-
to-head comparative studies. This study aimed to establish the relative efficacy of
icatibant [Shire HGT] versus C1-esterase inhibitor concentrate (C1-INH) [CSL Beh-
ring], C1-INH [ViroPharma], rh-C1-INH [Pharming], and ecallantide [Dyax].
METHODS: A systematic literature review identified nine relevant randomised
clinical trials. Indirect comparison (IC) hazard ratios (HR) between treatments were
calculated using the methods of Bucher et al (1997) and Song et al (2003). To account
for trial heterogeneity, five sets of icatibant data were considered separately; three
clinical endpoint definitions (time to onset of primary symptom relief, time to
initial symptom improvement [subject-assessed], and time to onset of symptom
relief based on composite VAS score); and three rescue medication (RM) censoring
methods (no censoring [RMs ignored], censoring subjects who took RMs prior to
onset of symptom relief, and resetting time to onset of symptom relief to 24 h for
censored subjects) were considered separately in the ICs. RESULTS: The IC consid-
ered each of the 45 icatibant data/endpoint definition/RM censoring combinations.
HR estimates favoured (HR 1) 37/45 icatibant combinations versus C1-INH [CSL
Behring] 20 IU/kg (Median HR  1.39 [minimum 0.72, maximum 2.10]), 45/45 (29
statistically significant) versus C1-INH [CSL Behring] 10 IU/kg (Median HR  2.19
[minimum 1.07, maximum 3.39]), 32/45 versus C1-INH [ViroPharma] (Median HR 
1.36 [minimum 0.63, maximum 2.22]), 24/45 versus rh-C1-INH 50 IU/kg (Median HR
 1.04 [minimum 0.48, maximum 1.70]), and 43/45 versus ecallantide (Median HR
1.67 [minimum 0.75, maximum 2.66]). CONCLUSIONS: Icatibant showed improved
time to symptom relief when compared with C1-INH [CSL Behring] 10 IU/kg. No
clear differences were evident versus either C1-INH [CSL Behring] 20 IU/kg (SmPC
dosing) or the three other HAE treatments.
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SWEDISH ADAPTATION OF CZECH PHARMACOECONOMIC COMPARISON OF
TREATMENTS IN HAEMOPHILIA PATIENTS WITH INHIBITORS
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OBJECTIVES: Due to limited patient population and scarcity of real-world data,
performing health economic analyses in haemophilia patients with inhibitors is
challenging. A recent publication based on national data from the Czech Republic
presented a health economic comparison of recombinant activated factor VII (rF-
VIIa) and plasma-derived activated prothrombin complex concentrate (pd-aPCC) in
the treatment of bleedings in inhibitor patients. The objective of this study was to
adapt the findings from the Czech study to a Swedish setting. METHODS: Aggre-
gated published data were used for the analysis. Real-life resource utilization (by-
passing agents and hospitalizations) were derived from the Czech study. Swedish
costs were obtained by multiplying each resource with corresponding unit costs
obtained from public price lists. RESULTS: Mean dose per bleeding in the rFVIIa
group was 17000 mcg, while the corresponding figure for the pd-aPCC group was
23000 IU. Mean number of hospital days was 0.9 in the rFVIIa group and 3.2 in the
pd-aPCC group. Mean total cost per bleeding was almost twice as high in the pd-
aPCC group (SEK 225549) compared to the rFVIIa group (SEK 112298). There was a
large variability in resource use across bleeding episodes in both treatment groups.
CONCLUSIONS: The Swedish adaptation of the Czech health economic analysis of
rFVIIa and pd-aPCC showed that rFVIIa treatment was associated with substan-
tially lower costs per bleeding episode. The main limitation of this analysis in a
Swedish setting is that it is based on data from the Czech Republic. However, Czech
data should have relevance in a Swedish setting, considering the large similarities
between the countries regarding incidence and severity of the disease, manage-
ment of haemophilia, availability of health care resources, clinical practice pat-
terns, and relative prices. A strength of the analysis is that it is based on real-life
data.
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OBJECTIVES: Innovative treatments have transformed CML into a chronic disease
mostly managed in outpatient care. This study aimed to estimate the cost of treat-
ing patients with CML as well as the cost of managing the adverse events of the
disease. METHODS: A retrospective study was performed in the Heamatology De-
partment of Evangelismos General Hospital of Athens. Study sample consisted of
all patients (n79) who visited the hematology of outpatient Units of the hospital
from January 2007 to December 2011. Cost analysis was based on patient’s direct
cost, including cost of personnel, supplies, medication, laboratory and imaging
tests, infrastructure and various other on-site costs. Mean annual cost per patient
is elaborated separately in outpatient and inpatient care. Inpatient costs mostly
refer to the treatment of adverse events. Cost analysis is based on each year’s NHS
prices transformed in 2012 values and the National Health System (NHS) persective
has been used. RESULTS: The mean annual cost per patient in chronic phase of
Myeloid Leukemia treated in outpatient care is estimated at €22.972. The most
frequent adverse events managed were anemia (n7, 9% of patients) and neutro-
penia (n12, 15% of patients). Mean hospitalization cost per patient due to the
treatment of adverse events is as follows: for anemia €2.193 and neutropenia of
€1.312. The cost of treating anemia corresponds to 9.5% of the overall cost of treat-
ment and the cost of neutropenia about 5,7%. Annual cost of newly diagnosed
patients in 2011 was estimated at €8.339, 57% lower than the respective cost of
patients treated in 2007 (€14.652). CONCLUSIONS: Innovative treatments for CML
have resulted in treating patients in outpatient care with lower adverse events and
consequently lower cost. Under the current economic restriction Greece is facing
as well as the recent implementation of Diagnoses Related Groups, information on
treatment costs provides a tool to assess NHS hospitals’ performance.
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PILOT COST STUDY OF CHRONIC MIELOID LEUKEMIA THERAPY
Kamusheva M1, Georgieva S2, Stoimenova A1, Petrova G1
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OBJECTIVES: To analyze the direct and indirect cost of therapy of chronic myeloid
leukemia (CML) from the society perspective within one year. METHODS: It is a
prospective observational cost study of 36 patients treated at the University Hos-
pital “Alexandrovska”. The pharmacotherapy cost, GP and specialists visits cost,
hospitalization cost were collected as direct medical costs. National health insur-
ance fund and hospital tariff were used as unit cost sources. Days out of work were
also collected and multiplied with the average monthly income to gather the indi-
rect costs. RESULTS: The observed 36 patients (average age 51 years) remain 14% of
all diagnosed and actively treated CML population. Average monthly cost of ther-
apy is 3130 Euro (SD 775 Euro) thus reaching 37 560 Euro per year per patient. On
imatinib therapy were found 20 of the observed patients, 8 on dasatinib, and 2 on
nilotinib. 6 patients were switched to different medicine during the period, out of
them 5 from imatinib to nilotinib due to disease progression and 1 from imatinib to
dasatinib due to intolerance development. On average 5 visits were performed per
year to GP and from 4-12 to specialists. The cost of the respective visits is 18 (SD5),
and 34 euro per patient. Only 6 patients were hospitalized during the therapy
switch and their cost was found to be 1098 Euro. The total number of days out of
work was found to be 103 days for the employed patients thus consuming incomes
for 5 months. Relative share of the direct and indirect cost is 92% to 8%, respec-
tively. Out of the direct medical cost medicines account for near 90%.
CONCLUSIONS: CML consumes mainly direct medical costs where the medicines
are the main cost driver.
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LONG-TERM MEDICAL COSTS AND LIFE EXPECTANCY OF ACUTE MYELOID
LEUKAEMIA: A PROBABILISTIC DECISION MODEL
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1University of York, York, UK, 2University of Oslo, Oslo, Norway
OBJECTIVES: Acute Myeloid Leukaemia (AML) can be diagnosed at any age and
accounts for approximately one third of all leukaemia diagnoses. Treatment,
which can be given with supportive and/or curative intent, is considered expensive
compared to other cancers. Despite this, no long-term predictive models have been
developed for AML, mainly due to the complexities associated with this disease.
Thus, the aim of the current study was to develop an AML model (based on a UK
cohort) that would allow cost and life expectancy results to be expressed at popu-
lation level. METHODS: The model developed in this study combined a decision
tree with several Markov models. This was in order to reflect the complexity of
health states, treatments, and prognostic factors (such as age and response to
chemotherapy) of AML. The model was simulated over a life cycle of 60 months and
results were contrasted between two age-groups and over different treatment
pathways. Probabilistic modelling was also implemented in order to capture the
potential uncertainties of input parameters. Transition probabilities, life expectan-
cies and costs were derived from the NHS Hospital Episode Statistics (HES) and a UK
population-based database from the Haematological Malignancy Research Net-
work (HMRN, www.hmrn.org). RESULTS: The expected five year medical cost and
life expectancy for the elderly patients (60) were £22,538 and 8.5 months respec-
tively, and for the young adult patients (18-60) £82,266 and 33.78 months respec-
tively. The model was validated by the fact that the predicted results captured 92%
of the actual costs, while it also demonstrated good fit of the actual survival
outcomes. CONCLUSIONS: Costs and life expectancy of AML vary according to
patient characteristics and treatment pathways. It is expected that future applica-
tion of the AML model developed in this study could be used to evaluate new
diagnostic tools/treatments and to support health care decision makers.
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IMPACT OF CHRONIC IMMUNE-MEDIATED INFLAMMATORY DISEASES ON
WORK PRODUCTIVITY: LITERATURE REVIEW
Granados D1, Depont F2, Chevreul K3
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OBJECTIVES: To quantify the work productivity loss induced by chronic immune-
mediated inflammatory diseases. METHODS: A systematic and computerized
search was performed in the literature published in English from 2000 to 2011 in
Pubmed. The search terms were: ‘crohn disease’, ‘spondylitis, ‘ankylosing’, ‘psori-
asis’, ‘rheumatoid arthritis’, ‘work productivity’, ‘productivity’, ‘absenteeism’, ‘sick
leave’ and ‘employment status’. Number of days of absenteeism and presenteeism,
and their estimated costs were extracted. Mean duration of work productivity loss
per patient was annualized. Mean costs per patient were annualized, converted in
Euros and actualized to 2010 using exchange rates and price indexes provided by
the Organisation for Economic Co-operation and Development. RESULTS: Eighteen
publications were analyzed: 4 for rheumatoid arthritis, 6 for ankylosing spondyli-
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